tetano
Editor, Senior Moderator
Rev Soc Bras Med Trop
. 2022 May 20;55:e00632022.
doi: 10.1590/0037-8682-0063-2022. eCollection 2022.
Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccine): follow-up after the second and third booster doses
Walter de Araujo Eyer-Silva[SUP] 1 [/SUP], Lidiane Simões de Carvalho Paes Leme[SUP] 1 [/SUP]
Affiliations
Abstract
Mass vaccination campaigns are essential to control the ongoing novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic. The Covishield vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, which contains the full-length structural spike protein of SARS-CoV-2. Occasionally, it can lead to cutaneous reactions that contribute to fear of vaccination, hesitancy, and incomplete vaccination schedules. We report a case of facial angioedema following the first dose of Covishield in a 63-year-old woman with no previous history of allergies or hypersensitivity to drugs or vaccines. No rebound of angioedema was recorded after the second homologous and third heterologous doses.
. 2022 May 20;55:e00632022.
doi: 10.1590/0037-8682-0063-2022. eCollection 2022.
Facial Angioedema after the first dose of Covishield (adenovirus-vectored severe acute respiratory syndrome coronavirus 2 vaccine): follow-up after the second and third booster doses
Walter de Araujo Eyer-Silva[SUP] 1 [/SUP], Lidiane Simões de Carvalho Paes Leme[SUP] 1 [/SUP]
Affiliations
- PMID: 35613221
- DOI: 10.1590/0037-8682-0063-2022
Abstract
Mass vaccination campaigns are essential to control the ongoing novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic. The Covishield vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, which contains the full-length structural spike protein of SARS-CoV-2. Occasionally, it can lead to cutaneous reactions that contribute to fear of vaccination, hesitancy, and incomplete vaccination schedules. We report a case of facial angioedema following the first dose of Covishield in a 63-year-old woman with no previous history of allergies or hypersensitivity to drugs or vaccines. No rebound of angioedema was recorded after the second homologous and third heterologous doses.